135 related articles for article (PubMed ID: 30457869)
1. Selective Inhibitors of Human Neuraminidase 1 (NEU1).
Guo T; Héon-Roberts R; Zou C; Zheng R; Pshezhetsky AV; Cairo CW
J Med Chem; 2018 Dec; 61(24):11261-11279. PubMed ID: 30457869
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.
Luzina IG; Lillehoj EP; Lockatell V; Hyun SW; Lugkey KN; Imamura A; Ishida H; Cairo CW; Atamas SP; Goldblum SE
J Pharmacol Exp Ther; 2021 Jan; 376(1):136-146. PubMed ID: 33139318
[TBL] [Abstract][Full Text] [Related]
3. Selective Inhibitors of Human Neuraminidase 3.
Guo T; Dätwyler P; Demina E; Richards MR; Ge P; Zou C; Zheng R; Fougerat A; Pshezhetsky AV; Ernst B; Cairo CW
J Med Chem; 2018 Mar; 61(5):1990-2008. PubMed ID: 29425031
[TBL] [Abstract][Full Text] [Related]
4. Identification of selective inhibitors for human neuraminidase isoenzymes using C4,C7-modified 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analogues.
Zhang Y; Albohy A; Zou Y; Smutova V; Pshezhetsky AV; Cairo CW
J Med Chem; 2013 Apr; 56(7):2948-58. PubMed ID: 23530623
[TBL] [Abstract][Full Text] [Related]
5. The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.
Hyun SW; Liu A; Liu Z; Cross AS; Verceles AC; Magesh S; Kommagalla Y; Kona C; Ando H; Luzina IG; Atamas SP; Piepenbrink KH; Sundberg EJ; Guang W; Ishida H; Lillehoj EP; Goldblum SE
Glycobiology; 2016 Aug; 26(8):834-49. PubMed ID: 27226251
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1).
Magesh S; Moriya S; Suzuki T; Miyagi T; Ishida H; Kiso M
Bioorg Med Chem Lett; 2008 Jan; 18(2):532-7. PubMed ID: 18068975
[TBL] [Abstract][Full Text] [Related]
7. Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.
Albohy A; Zhang Y; Smutova V; Pshezhetsky AV; Cairo CW
ACS Med Chem Lett; 2013 Jun; 4(6):532-7. PubMed ID: 24900705
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
Richards MR; Guo T; Hunter CD; Cairo CW
Bioorg Med Chem; 2018 Oct; 26(19):5349-5358. PubMed ID: 29903413
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of selective inhibitors against V. cholerae sialidase and human cytosolic sialidase NEU2.
Khedri Z; Li Y; Cao H; Qu J; Yu H; Muthana MM; Chen X
Org Biomol Chem; 2012 Aug; 10(30):6112-20. PubMed ID: 22641268
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors.
Magesh S; Suzuki T; Miyagi T; Ishida H; Kiso M
J Mol Graph Model; 2006 Oct; 25(2):196-207. PubMed ID: 16427342
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid.
Zou Y; Albohy A; Sandbhor M; Cairo CW
Bioorg Med Chem Lett; 2010 Dec; 20(24):7529-33. PubMed ID: 21036040
[TBL] [Abstract][Full Text] [Related]
12. Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Rota P; La Rocca P; Piccoli M; Montefiori M; Cirillo F; Olsen L; Orioli M; Allevi P; Anastasia L
ChemMedChem; 2018 Feb; 13(3):236-240. PubMed ID: 29231283
[TBL] [Abstract][Full Text] [Related]
13. Aglycone-focused randomization of 2-difluoromethylphenyl-type sialoside suicide substrates for neuraminidases.
Kai H; Hinou H; Nishimura S
Bioorg Med Chem; 2012 Apr; 20(8):2739-46. PubMed ID: 22410247
[TBL] [Abstract][Full Text] [Related]
14. Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Howlader MA; Guo T; Chakraberty R; Cairo CW
ACS Chem Biol; 2020 Jun; 15(6):1328-1339. PubMed ID: 32310634
[TBL] [Abstract][Full Text] [Related]
15. Analysis of inhibitor binding in influenza virus neuraminidase.
Smith BJ; Colman PM; Von Itzstein M; Danylec B; Varghese JN
Protein Sci; 2001 Apr; 10(4):689-96. PubMed ID: 11274459
[TBL] [Abstract][Full Text] [Related]
16. A strategy for neuraminidase inhibitors using mechanism-based labeling information.
Hinou H; Miyoshi R; Takasu Y; Kai H; Kurogochi M; Arioka S; Gao XD; Miura N; Fujitani N; Omoto S; Yoshinaga T; Fujiwara T; Noshi T; Togame H; Takemoto H; Nishimura S
Chem Asian J; 2011 Apr; 6(4):1048-56. PubMed ID: 21305698
[TBL] [Abstract][Full Text] [Related]
17. Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses.
Abdulkhalek S; Szewczuk MR
Cell Signal; 2013 Nov; 25(11):2093-105. PubMed ID: 23827939
[TBL] [Abstract][Full Text] [Related]
18. Human Neuraminidases: Structures and Stereoselective Inhibitors.
Bourguet E; Figurska S; Fra Czek MM
J Med Chem; 2022 Feb; 65(4):3002-3025. PubMed ID: 35170942
[TBL] [Abstract][Full Text] [Related]
19. In Cellulo Crystallization of Human Neuraminidase 1 and Biological Roles of
Tsukimoto J; Takeuchi Y; Horii Y; Iniwa T; Fukushi Y; Nishioka SI; Itoh K
ACS Appl Bio Mater; 2022 Jan; 5(1):205-213. PubMed ID: 35014832
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors.
Jia R; Zhang J; Ai W; Ding X; Desta S; Sun L; Sun Z; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
Eur J Med Chem; 2019 Sep; 178():64-80. PubMed ID: 31176096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
